Share 'Santhera Presents Clinical Data of Catena® in Duchenne Muscular Dystrophy at the 2011 Congress of the World Muscle Society'
Liestal, Switzerland, October 19, 2011 - Santhera Pharmaceuticals (SIX: SANN)announced today that it will present data from the 2-year open-label study(DELPHI-E study) evaluating Catena® for the treatment of Duchenne MuscularDystrophy [1], one of the most common and devastating types of musculardystrophy. The findings indicate that Catena® slowed the decline in respirat…
You can share this discussion in two ways…
© 2022 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
